Genfit Among the Strongest Gainers in the SBF 120, Up 36% in One Month
The Lille-based biotech specializing in liver and metabolic diseases extends its rebound mid-session, in a well-oriented Paris market. The move follows the trend of recent weeks, after a quarterly publication that had triggered a two-way reaction in the stock.
A Rebound That Places Genfit Among the Strongest Gainers in the SBF 120
Genfit shares gain 2.93% to €11.26 during the session, placing the stock among the strongest gainers in the SBF 120, while the index rises 0.7%. However, the stock fell 12% on November 6 following its third-quarter results, before recovering.
The stock now shows a gain of nearly 36% over one month, but remains down 13.1% over three months, so this rebound recovers only part of the decline recorded during the quarter.
The share price stands 10.3% above its 20-period moving average (MM20) and its 200-period moving average (MM200), and 8.9% above its 50-period moving average (MM50). It is also approaching the €11.46 resistance level, which the stock had broken on November 4 before pulling back.
Iqirvo Royalties and Funding Through 2028: What the November 5 Publication Says
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
During the publication of its third-quarter financial information on November 5, 2026, Genfit reported Iqirvo royalties up 188% over nine months, to €36.3 million. Meanwhile, total revenue declined, to €36.4 million compared with €39.2 million a year earlier.
The company states that this trajectory allows it to finance its activities beyond the end of 2028, and says it is reinforced in its expectation of the possible receipt of a new commercial milestone payment.
The royalties come almost entirely from Ipsen, which markets the product. Medicare has also approved reimbursement for the NASHnext® test in August. On the research side, the first phase 2a data in ACLF are expected in 2027.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 36,4 millions d'euros
Quarterly revenue: 36,4 millions d'euros
Revenue growth: -7,1 %
Guidance from the release
« conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
